<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31088809</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2473-9537</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>3</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Blood advances</Title>
          <ISOAbbreviation>Blood Adv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.</ArticleTitle>
        <Pagination>
          <StartPage>1553</StartPage>
          <EndPage>1562</EndPage>
          <MedlinePgn>1553-1562</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1182/bloodadvances.2018030007</ELocationID>
        <Abstract>
          <AbstractText>The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity than ibrutinib. We evaluated the safety and efficacy of 100 mg of acalabrutinib twice daily or 200 mg once daily in patients with CLL who discontinued ibrutinib because of intolerance as determined by the investigators. Among 33 treated patients (61% men; median age, 64 years; range, 50-82 years), median duration of prior ibrutinib treatment was 11.6 months (range, 1-62 months); median time from ibrutinib discontinuation to acalabrutinib start was 47 days (range, 3-331 days). After a median of 19.0 months (range, 0.2-30.6 months), 23 patients remained on acalabrutinib; 10 had discontinued (progressive disease, n = 4; AEs, n = 3). No acalabrutinib dose reductions occurred. During acalabrutinib treatment, the most frequent AEs included diarrhea (58%), headache (39%), and cough (33%). Grade 3/4 AEs occurred in 58%, most commonly neutropenia (12%) and thrombocytopenia (9%). Of 61 ibrutinib-related AEs associated with intolerance, 72% did not recur and 13% recurred at a lower grade with acalabrutinib. Overall response rate was 76%, including 1 complete and 19 partial responses and 5 partial responses with lymphocytosis. Among 25 responders, median duration of response was not reached. Median progression-free survival (PFS) was not reached; 1-year PFS was 83.4% (95% confidence interval, 64.5%-92.7%). Acalabrutinib was well tolerated with a high response rate in patients who were previously intolerant to ibrutinib. This trial was registered at www.clinicaltrials.gov as #NCT02029443.</AbstractText>
          <CopyrightInformation>© 2019 by The American Society of Hematology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Awan</LastName>
            <ForeName>Farrukh T</ForeName>
            <Initials>FT</Initials>
            <Identifier Source="ORCID">0000-0003-1813-9812</Identifier>
            <AffiliationInfo>
              <Affiliation>Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schuh</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Jennifer R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Dana-Farber Cancer Institute, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Furman</LastName>
            <ForeName>Richard R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pagel</LastName>
            <ForeName>John M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Swedish Cancer Institute, Seattle, WA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hillmen</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0001-5617-4403</Identifier>
            <AffiliationInfo>
              <Affiliation>St. James's University Hospital, Leeds, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stephens</LastName>
            <ForeName>Deborah M</ForeName>
            <Initials>DM</Initials>
            <Identifier Source="ORCID">0000-0001-9188-5008</Identifier>
            <AffiliationInfo>
              <Affiliation>Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woyach</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bibikova</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Charuworn</LastName>
            <ForeName>Prista</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frigault</LastName>
            <ForeName>Melanie M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Oncology Translational Science, and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamdy</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Linghu</LastName>
            <ForeName>Bolan</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology Biosciences, IMED Biotech Unit, AstraZeneca, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Min Hui</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Byrd</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center, Columbus, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02029443</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R35 CA197734</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA177292</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Blood Adv</MedlineTA>
        <NlmUniqueID>101698425</NlmUniqueID>
        <ISSNLinking>2473-9529</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X70OSD4VX</RegistryNumber>
          <NameOfSubstance UI="C551803">ibrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D000077329">Agammaglobulinaemia Tyrosine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C000625949">BTK protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JAC85A2161</RegistryNumber>
          <NameOfSubstance UI="D000225">Adenine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000225" MajorTopicYN="N">Adenine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077329" MajorTopicYN="N">Agammaglobulinaemia Tyrosine Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Conflict-of-interest disclosure: F.T.A. has been a consultant for AbbVie, Janssen, Gilead, Sunesis, AstraZeneca, Genentech, and Pharmacyclics, received research funding from Innate Pharma and Pharmacyclics, and served on speakers’ bureaus for AstraZeneca and AbbVie. A.S. has been a consultant for and has received honoraria from AbbVie, Gilead, GlaxoSmithKline, Janssen, Novartis, and Roche. J.R.B. has been a consultant for AbbVie, Astellas Pharma, AstraZeneca, Celgene, Gilead, Verastem Pharmaceuticals, Janssen, Pfizer, Pharmacyclics, Redx, Roche/Genentech, and Sun BioPharma. R.R.F. has been a consultant for AbbVie, Acerta Pharma, Genentech, Gilead, Incyte, Janssen, Loxo Oncology, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem. J.M.P. has been a consultant for Gilead and Pharmacyclics and has equity ownership in and received research funding from Actinium Pharmaceuticals. P.H. has been a consultant for AbbVie, Acerta Pharma, Alexion Pharmaceuticals, Gilead, and Janssen, has received honoraria from AbbVie, Acerta Pharma, Alexion Pharmaceuticals, Gilead, and Janssen, and has received research funding from AbbVie, Gilead, Janssen, GlaxoSmithKline, Pharmacyclics, and Roche. D.M.S. has received research funding from the Lymphoma Research Foundation. J.W. has been a consultant for Janssen and received research funding from Acerta, AbbVie, Karyopharm, and Morphosys. P.C. is an employee of Acerta Pharma. M.M.F. is an employee of and holds stock in AstraZeneca. B.L. is an employee of AstraZeneca. A.H. and R.I. are patent holders and employees of Acerta Pharma and have equity ownership. E.B., M.H.W., and P.P. are employees of Acerta Pharma and have equity ownership. J.C.B. has received research funding from Acerta Pharma, Genentech, Janssen, and Pharmacyclics.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31088809</ArticleId>
        <ArticleId IdType="pmc">PMC6517672</ArticleId>
        <ArticleId IdType="doi">10.1182/bloodadvances.2018030007</ArticleId>
        <ArticleId IdType="pii">bloodadvances.2018030007</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Union for International Cancer Control. Chronic lymphocytic leukemia: 2014 review of cancer medicines on the WHO List of Essential Medicines. https://www.who.int/selection_medicines/committees/expert/20/applications/CLL.pdf. Accessed 1 May 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Burger JA, Wiestner A. 
Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18(3):148-167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29348577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. 
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014;32(27):3039-3047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4162500</ArticleId>
            <ArticleId IdType="pubmed">25049322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Furman RR, Coutre SE, et al. . 
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3772525</ArticleId>
            <ArticleId IdType="pubmed">23782158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Brown JR, O’Brien S, et al. ; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tedeschi A, Barr PM, et al. ; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Furman RR, Coutre SE, et al. . 
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4400288</ArticleId>
            <ArticleId IdType="pubmed">25700432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanan-Khan A, Cramer P, Demirkan F, et al. ; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26655421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain P, Keating M, Wierda W, et al. . 
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-2067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4467871</ArticleId>
            <ArticleId IdType="pubmed">25573991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain P, Thompson PA, Keating M, et al. . 
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268-2273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5980235</ArticleId>
            <ArticleId IdType="pubmed">28171709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Claro RA, McGinn KM, Verdun N, et al. . 
FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586-3590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26275952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharman JP, Black-Shinn JL, Clark J, Bitman B. 
Understanding ibrutinib treatment discontinuation patterns for chronic lymphocytic leukemia [abstract]. Blood. 2017;130(suppl 1). Abstract 4060.</Citation>
        </Reference>
        <Reference>
          <Citation>Mato AR, Hill BT, Lamanna N, et al. . 
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050-1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28453705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Nabhan C, Thompson MC, et al. . 
Toxicities and outcomes of 621 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874-879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5927982</ArticleId>
            <ArticleId IdType="pubmed">29419429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honigberg LA, Smith AM, Sirisawad M, et al. . 
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2919935</ArticleId>
            <ArticleId IdType="pubmed">20615965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barf T, Covey T, Izumi R, et al. . 
Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240-252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O’Brien S, et al. . 
Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Department of Health and Human Services, Public Health Service, US Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacology/toxicology NDA review and evaluation (NDA 205552; Imbruvica [ibrutinib]). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000PharmR.pdf. Accessed 1 May 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith-Garvin JE, Koretzky GA, Jordan MS. 
T cell activation. Annu Rev Immunol. 2009;27(1):591-619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2740335</ArticleId>
            <ArticleId IdType="pubmed">19132916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowell CA.
Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol. 2011;3(3):a002352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3039931</ArticleId>
            <ArticleId IdType="pubmed">21068150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atherly LO, Brehm MA, Welsh RM, Berg LJ. 
Tec kinases Itk and Rlk are required for CD8+ T cell responses to virus infection independent of their role in CD4+ T cell help. J Immunol. 2006;176(3):1571-1581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16424186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrne JC, Ní Gabhann J, Stacey KB, et al. . 
Bruton’s tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin. J Immunol. 2013;190(10):5207-5215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23596312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da Roit F, Engelberts PJ, Taylor RP, et al. . 
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica. 2015;100(1):77-86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4281316</ArticleId>
            <ArticleId IdType="pubmed">25344523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng M, Chen JY, Weissman-Tsukamoto R, et al. . 
Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci USA. 2015;112(7):2145-2150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4343163</ArticleId>
            <ArticleId IdType="pubmed">25646432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golay J, Ubiali G, Introna M. 
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B-cells with CD20 antibodies. Haematologica. 2017;102(10):e400-e403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5622871</ArticleId>
            <ArticleId IdType="pubmed">28642301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. . 
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123(12):1957-1960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962169</ArticleId>
            <ArticleId IdType="pubmed">24652965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oda A, Ikeda Y, Ochs HD, et al. . 
Rapid tyrosine phosphorylation and activation of Bruton’s tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood. 2000;95(5):1663-1670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10688822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senis YA, Mazharian A, Mori J. 
Src family kinases: at the forefront of platelet activation. Blood. 2014;124(13):2013-2024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4186533</ArticleId>
            <ArticleId IdType="pubmed">25115887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Rule S, Zinzani PL, et al. . 
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659-667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29241979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel V, Balakrishnan K, Bibikova E, et al. . 
Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23(14):3734-3743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5491371</ArticleId>
            <ArticleId IdType="pubmed">28034907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Wierda WG, Schuh A, et al. . 
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from the phase 1/2 ACE-CL-001 study [abstract]. Blood. 2017;130(suppl 1). Abstract 498.</Citation>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, et al. ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheson BD, Ansell S, Schwartz L, et al. . 
Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489-2496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27574190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai Z, Markovets A, Ahdesmaki M, et al. . 
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11):e108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4914105</ArticleId>
            <ArticleId IdType="pubmed">27060149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AstraZeneca. Clinical trials disclosure commitment. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Accessed 1 May 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Döhner H, Stilgenbauer S, Benner A, et al. . 
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11136261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Covey T, Gulrajani M, Cheung J, et al. . 
Pharmacodynamic evaluation of acalabrutinib in relapsed/refractory and treatment-naive patients with chronic lymphocytic leukemia (CLL) in the phase 1/2 ACE-CL-001 study [abstract]. Blood. 2017;130(suppl 1). Abstract 1741.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
